Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAV vs AVF for hemodialysis access in ESRD
NCT03183245Phase 3Completed
- Sponsor
- Humacyte
- Start
- Sep 2017
- Primary completion
- Apr 2024
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Humacyte. Primary endpoints: Proportion of subjects with functional patency at 6 months post study access creation and Proportion of subjects with secondary patency of SA at 12 months post SA creation. Started Sep 2017; status: completed.
Beyond the preview
Go deeper on NCT03183245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03183245.